ID
45994
Beschreibung
Principal Investigator: Arul Chinnaiyan, University of Michigan, MI, USA MeSH: Prostatic Neoplasms https://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs000915 Most prostate cancer deaths are caused by metastatic, castration resistant disease (mCRPC). To develop a precision medicine framework for mCRPC, we established a multi-institutional, international clinical sequencing infrastructure to enroll and carry out prospective whole exome and transcriptome sequencing of tumors from a cohort of mCRPC patients. We obtained high quality DNA and RNA sequence data from 150 bone or soft tissue biopsies. Central pathology revealed high-grade adenocarcinoma with only four cases (3.6%) showing neuroendocrine differentiation. Aberrations of AR, ETS genes, TP53 and PTEN were frequent (40-60% of cases), with TP53 and AR alterations being the most enriched in mCRPC compared to primary prostate cancer. We identified novel genomic alterations in PIK3CA/B (fusions and mutations); R-spondin, BRAF and RAF1 (fusions); APC (inactivating mutations); delta-catenin (missense mutations); and ZBTB16/PLZF (homozygous deletions). Aberrations of BRCA2, BRCA1 and ATM were observed at substantially higher frequencies (19.3% overall) than seen in primary prostate cancers, with 56% of these being exclusively somatic. Putative driver gene alterations were identified in nearly all patients, and over half also harbored driver gene fusions, homozygous deletions and/or amplifications. Moreover, 89% of patients harbored a clinically actionable aberration including 62.7% with aberrations in AR, 65% in other cancer-related genes, and 8% with actionable pathogenic germline alterations. Overall, integrative clinical sequencing analysis can be safely and efficiently performed in mCRPC, yields findings that may be actionable for enrolling patients in clinical trials of targeted therapies, and may inform the basis of individual clinical responses.
Link
Stichworte
Versionen (1)
- 14.04.24 14.04.24 - Madita Rudolph
Rechteinhaber
Arul Chinnaiyan, University of Michigan, MI, USA
Hochgeladen am
14. April 2024
DOI
Für eine Beantragung loggen Sie sich ein.
Lizenz
Creative Commons BY 4.0
Modell Kommentare :
Hier können Sie das Modell kommentieren. Über die Sprechblasen an den Itemgruppen und Items können Sie diese spezifisch kommentieren.
Itemgroup Kommentare für :
Item Kommentare für :
Um Formulare herunterzuladen müssen Sie angemeldet sein. Bitte loggen Sie sich ein oder registrieren Sie sich kostenlos.
dbGaP phs000915 Integrative Clinical Sequencing Analysis of Metastatic Castration Resistant Prostate Cancer Reveals a High Frequency of Clinical Actionability
Sample ID, sample type [tumor or normal tissue], and analyte type of sample obtained from participants with prostate cancer and involved in the "Stand Up To Cancer East Coast Prostate Cancer Research Group" project.
- StudyEvent: SEV1
- Subject ID and consent group of participants with prostate cancer and involved in the "Stand Up To Cancer East Coast Prostate Cancer Research Group" project.
- Subject ID, sample ID, and sample use of participants with prostate cancer and involved in the "Stand Up To Cancer East Coast Prostate Cancer Research Group" project.
- Subject ID and main disease for which the participant has been asked to donate a sample for study of participants with prostate cancer and involved in the "Stand Up To Cancer East Coast Prostate Cancer Research Group" project.
- Sample ID, sample type [tumor or normal tissue], and analyte type of sample obtained from participants with prostate cancer and involved in the "Stand Up To Cancer East Coast Prostate Cancer Research Group" project.
Ähnliche Modelle
Sample ID, sample type [tumor or normal tissue], and analyte type of sample obtained from participants with prostate cancer and involved in the "Stand Up To Cancer East Coast Prostate Cancer Research Group" project.
- StudyEvent: SEV1
- Subject ID and consent group of participants with prostate cancer and involved in the "Stand Up To Cancer East Coast Prostate Cancer Research Group" project.
- Subject ID, sample ID, and sample use of participants with prostate cancer and involved in the "Stand Up To Cancer East Coast Prostate Cancer Research Group" project.
- Subject ID and main disease for which the participant has been asked to donate a sample for study of participants with prostate cancer and involved in the "Stand Up To Cancer East Coast Prostate Cancer Research Group" project.
- Sample ID, sample type [tumor or normal tissue], and analyte type of sample obtained from participants with prostate cancer and involved in the "Stand Up To Cancer East Coast Prostate Cancer Research Group" project.
C1299222 (UMLS CUI [1,2])
C0443354 (UMLS CUI [1,2])
C0012854 (UMLS CUI [1,3])
C0035668 (UMLS CUI [1,4])
Keine Kommentare